Literature DB >> 10749319

Therapeutic role for bismuth compounds in TNBS-induced colitis in the rat.

T C Peterson1, C E Cleary, A M Shaw, D A Malatjalian, S J Veldhuyzen van Zanten.   

Abstract

The 2,4,6-trinitrobenzene sulfonic acid (TNBS) -induced model of chronic inflammation of the rat colon was used to determine the efficacy of bismuth subsalicylate (BSS), bismuth subcitrate (CBS), and 5-aminosalicylic acid (5-ASA) administered in enema form. A novel bismuth compound 1, 2-bis[2-(1,3-dithiobismolane)thio]ethane [Bi2(EDT)3] was also tested. On day 1 colitis was induced with 50 mg TNBS/50% ethanol in female Sprague-Dawley rats, while controls received a saline enema. On day 3, twice-daily treatment with enemas of either saline, BSS, CBS, Bi2(EDT)3, or 5-ASA were initiated in the colitis and control rats. All rats were killed on day 14, and the colons excised, weighed, rated macroscopically, and then fixed for hematoxylin and eosin staining. Blinded microscopic scoring was used to determine injury and healing in all groups. Colon mass and macroscopic scores were increased (P < 0.05) in the group of rats treated with TNBS (N = 16) compared to saline controls (N = 12). Colon mass and macroscopic scores in controls treated with BSS (N = 4), CBS (N = 4), Bi2(EDT)3 (N = 4), and 5-ASA (N = 4) alone did not differ from saline control animals. Macroscopic scoring showed a decrease (P < 0.05) in the degree of damage in the group of rats treated with TNBS plus BSS (N = 15), TNBS plus Bi2(EDT)3 (N = 10) and TNBS plus CBS (N = 4) compared to the group of rats treated with TNBS plus saline (N = 16). A decrease (P < 0.05) in injury and an increase (P < 0.05, Kruskal-Wallis) in healing was observed in the groups of rats treated with TNBS plus BSS, TNBS plus CBS, and TNBS plus 5-ASA compared to the group of rats treated with TNBS plus saline. It appeared that Bi2(EDT)3 was not protective against injury at the microscopic level but that the novel Bi2(EDT)3 has an effective healing capacity at the macroscopic level. We conclude that BSS and CBS decrease injury and/or promote healing as effectively as 5-ASA in this model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749319     DOI: 10.1023/a:1005476619923

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Tripotassium dicitrato bismuthate enemas in the treatment of ulcerative proctitis.

Authors:  E D Srivastava; G L Swift; S Wilkinson; G T Williams; B K Evans; J Rhodes
Journal:  Aliment Pharmacol Ther       Date:  1990-12       Impact factor: 8.171

Review 2.  The use of bismuth in gastroenterology. The ACG Committee on FDA-Related Matters. American College of Gastroenterology.

Authors:  B J Marshall
Journal:  Am J Gastroenterol       Date:  1991-01       Impact factor: 10.864

3.  Incrimination of anaerobic bacteria in the induction of experimental colitis.

Authors:  A García-Lafuente; M Antolín; F Guarner; E Crespo; A Salas; P Forcada; M Laguarda; J Gavaldá; J A Baena; J Vilaseca; J R Malagelada
Journal:  Am J Physiol       Date:  1997-01

Review 4.  Bismuth therapy in gastrointestinal diseases.

Authors:  S L Gorbach
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

5.  Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis.

Authors:  P Gionchetti; F Rizzello; A Venturi; M Ferretti; C Brignola; S Peruzzo; C Belloli; G Poggioli; M Miglioli; M Campieri
Journal:  Aliment Pharmacol Ther       Date:  1997-08       Impact factor: 8.171

Review 6.  The actions of bismuth in the treatment of Helicobacter pylori infection.

Authors:  J R Lambert; P Midolo
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

7.  Effect of acute pentoxifylline treatment in an experimental model of colitis.

Authors:  T C Peterson; K Davey
Journal:  Aliment Pharmacol Ther       Date:  1997-06       Impact factor: 8.171

8.  Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis.

Authors:  K D Fine; E L Lee
Journal:  Gastroenterology       Date:  1998-01       Impact factor: 22.682

Review 9.  Review article: safety of bismuth in the treatment of gastrointestinal diseases.

Authors:  L A Tillman; F M Drake; J S Dixon; J R Wood
Journal:  Aliment Pharmacol Ther       Date:  1996-08       Impact factor: 8.171

10.  Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.

Authors:  R D Pullan; S Ganesh; V Mani; J Morris; B K Evans; G T Williams; J Rhodes
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

View more
  4 in total

Review 1.  Role of the endothelium in inflammatory bowel diseases.

Authors:  Walter E Cromer; J Michael Mathis; Daniel N Granger; Ganta V Chaitanya; J Steven Alexander
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

2.  Bismuth ions inhibit the biological activity of non-amidated gastrins in vivo.

Authors:  Suzana Kovac; Su-Wen Loh; Shamilah Lachal; Arthur Shulkes; Graham S Baldwin
Journal:  Biochem Pharmacol       Date:  2011-12-08       Impact factor: 5.858

Review 3.  Microscopic colitis: A review of etiology, treatment and refractory disease.

Authors:  Tina Park; David Cave; Christopher Marshall
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

4.  Validation and optimization of experimental colitis induction in rats using 2, 4, 6-trinitrobenzene sulfonic acid.

Authors:  A Motavallian-Naeini; S Andalib; M Rabbani; P Mahzouni; M Afsharipour; M Minaiyan
Journal:  Res Pharm Sci       Date:  2012-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.